A Greater Platelet Dose May Yield Better Clinical Outcomes for Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review.
William A Berrigan, Zach Bailowitz, Anna Park...
https://pubmed.ncbi.nlm.nih.gov/38513880/Actively Recruiting
Led by University of California, San Francisco · Updated on 2026-08-18
20
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the differences in the quality of Platelet Rich Plasma PRP produced by two FDA-approved machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System. The study focuses on adults with knee osteoarthritis, a condition where the cartilage in the knee joint is worn down. The main goal is to compare the platelet amounts and function in PRP made by these two different systems and assess participants symptoms after receiving injections. Participants will be randomly assigned to receive PRP prepared by either the APEX Biologix XCELL PRP System or the Emcyte PurePRP Supraphysiologic Concentrating System. Both devices produce PRP injections that will be given to participants. The study observes and compares the composition of the PRP and tracks symptom changes over time. The treatments are administered once, and participants are monitored for several months afterward. During the study, researchers will measure cellular composition and platelet activation immediately after PRP preparation. Participants will be followed for up to six months to evaluate symptoms and quality of life using questionnaires such as the Western Ontario and McMaster Universities Arthritis Index WOMAC, Short Form-12 Health Survey, and Visual Analog Scale. Activity levels will also be monitored alongside PRP characteristics. This study aims to better understand how these two PRP preparation methods may affect knee osteoarthritis symptoms and platelet quality.
CONDITIONS
Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems
J
Joel Kopcow
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | PRP Injection made by APEX Biologix XCELL PRP System | PRP Injection made by Emcyte PurePRP Supraphysiologic Concentrating System |
|---|---|---|
| What it is | A PRP (platelet-rich plasma) injection prepared from the participant's own blood using the APEX Biologix XCELL PRP System device. | A PRP injection prepared from the participant's own blood using the Emcyte PurePRP Supraphysiologic Concentrating System device. |
| Role in the trial | Active comparator arm directly tested against an alternative PRP preparation system. | Active comparator arm directly tested against another PRP preparation system. |
| Primary use | Investigational use for knee osteoarthritis, aiming to analyze PRP cell composition and patient-reported outcomes. | Investigational use for knee osteoarthritis, aiming to analyze cellular PRP profile and patient-reported outcomes. |
| How it is given or performed | Blood is drawn and processed by the APEX Biologix XCELL PRP System to create PRP, which is then injected into the affected knee. | Blood is drawn and processed by the Emcyte PurePRP Supraphysiologic Concentrating System to create PRP, which is then injected into the affected knee. |
| Evidence status | The device delivers PRP for intra-articular use. There are no publicly posted results for this device in knee osteoarthritis regarding clinical improvement or specific cellular profiles. | The device delivers PRP for intra-articular injection. Published evidence in knee osteoarthritis reports variable preparation and cellular content, with limited clinical outcome data for this specific system. |
| Important limitations | PRP prepared by this system may differ in cellular yield and activation compared to other devices. Patient-level efficacy data in knee osteoarthritis are limited; long-term benefits and optimal cellular profile are not yet established. | Different PRP systems yield biologically distinct PRP products. Reliable device-specific clinical outcome data in knee osteoarthritis are sparse; optimal cellular composition and dosing are not fully determined. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Single treatment visit
Participants receive platelet rich plasma injections prepared by one of two different machines to compare platelet quality.
1 treatment visit
Duration - 6 months
Participants are monitored for up to 6 months to assess symptoms, activity levels, and platelet function outcomes.
Regular follow-up visits and assessments during this period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
William A Berrigan, Zach Bailowitz, Anna Park...
https://pubmed.ncbi.nlm.nih.gov/38513880/Harkirat Jawanda, Zeeshan A Khan, Alec A Warrier...
https://pubmed.ncbi.nlm.nih.gov/38331363/William Berrigan, Frances Tao, Joel Kopcow...
https://pubmed.ncbi.nlm.nih.gov/39331322/Ching-Hui Lee, Chih-Yi Lee, Huey-Ling You...
https://pubmed.ncbi.nlm.nih.gov/39134218/Connor G Ziegler, Rachel Van Sloun, Sabrina Gonzalez...
https://pubmed.ncbi.nlm.nih.gov/31034242/Emily A Sundman, Brian J Cole, Vasili Karas...
https://pubmed.ncbi.nlm.nih.gov/24192391/Voja Pavlovic, Milan Ciric, Vladimir Jovanovic...
https://pubmed.ncbi.nlm.nih.gov/28352802/Bhushan R Deshpande, Jeffrey N Katz, Daniel H Solomon...
https://pubmed.ncbi.nlm.nih.gov/27014966/Nazik Elgaddal, Julie D Weeks
https://pubmed.ncbi.nlm.nih.gov/39147377/Saeid Safiri, Ali-Asghar Kolahi, Emma Smith...
https://pubmed.ncbi.nlm.nih.gov/32398285/University of California, San Francisco
Lead Sponsor